LCN2 and coinfection: LCN2 was available in 130 of them, which were finally included in the study: 71 (54.6%) bacterial CAP (including co-infections with other bacteria or viruses), 42 (32.3%) CAP of unknown origin; and 17 (13.1%) viral CAP (including co-infections with another respiratory virus).